<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062395</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0206</org_study_id>
    <secondary_id>NCI-2021-00838</secondary_id>
    <secondary_id>2020-0206</secondary_id>
    <nct_id>NCT05062395</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography for the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis</brief_title>
  <official_title>Positron Emission Tomography for the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates positron emission tomography for the diagnosis of immune checkpoint&#xD;
      inhibitor-related myocarditis. Immune checkpoint inhibitors have shown promising results in&#xD;
      various malignancies however, several immune related adverse events have been described of&#xD;
      which myocarditis carries the highest reported mortality. Diagnostic procedures, such as&#xD;
      positron emission tomography, help find and diagnose myocarditis and provide functional or&#xD;
      disease activity information as opposed to the largely structural/anatomic information.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To prospectively evaluate the sensitivity, specificity, positive predictive value, and&#xD;
      negative predictive value of fludeoxyglucose F-18 (18 fluorodeoxyglucose) positive emission&#xD;
      tomography computed tomography (PET CT) for the diagnosis of immune checkpoint inhibitor&#xD;
      (ICI) related myocarditis.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To explore the clinical presentation and disease course of ICI-related myocarditis which&#xD;
      include presenting symptoms (chest pain, dyspnea, fatigue), time from ICI initiation to&#xD;
      symptom onset, hospitalization duration, time to peak troponin levels, and peak troponin&#xD;
      levels.&#xD;
&#xD;
      II. To evaluate biomarkers, including peak troponin, peak no probnp, admission troponin&#xD;
      level, and admission nt probnp level, and imaging modalities of ICI-related myocarditis which&#xD;
      include sensitivity, specificity, positive predictive value, and negative predictive value of&#xD;
      cardiac magnetic resonance imaging (MRI).&#xD;
&#xD;
      III. To determine the response to various treatments of ICI-related myocarditis which include&#xD;
      time to resolution of symptoms, hospitalization duration, and peak troponin value stratified&#xD;
      by treatment.&#xD;
&#xD;
      IV. To observe the long-term outcomes, including late decline in left ventricular ejection&#xD;
      fraction (LVEF) to &lt; 50%, and survival after ICI related myocarditis, and monitoring of&#xD;
      ICI-related myocarditis.&#xD;
&#xD;
      V. To assess differences in PET CT imaging results between patients on steroid therapy versus&#xD;
      not on steroid therapy for myocarditis.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive a low carbohydrate and high fat diet for 48-72 hours. Patients receive 18&#xD;
      fluorodeoxyglucose (FDG) then undergo PET CT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity, specificity, positive predictive value, and negative predictive value</measure>
    <time_frame>through study completion, an average of a year.</time_frame>
    <description>Calculations of sensitivity, specificity, positive predictive value, and negative predictive value and their 90% exact confidence intervals will be performed for the evaluation of positron emission tomography computed tomography considering endomyocardial biopsy as the gold standard. Secondary analysis of these parameters will be used considering the Bonaca et al diagnoses of immune checkpoint inhibitor (ICI)-related myocarditis as a new gold standard. Receiver operating characteristic (ROC) curve and the AUC value (area under the ROC curve) will be evaluated.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myocarditis Acute</condition>
  <arm_group>
    <arm_group_label>Observational (diet, FDG PET CT)</arm_group_label>
    <description>Patients receive a low carbohydrate and high fat diet for 48-72 hours. Patients receive FDG then undergo PET CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo FDG PET CT</description>
    <arm_group_label>Observational (diet, FDG PET CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Undergo FDG PET CT</description>
    <arm_group_label>Observational (diet, FDG PET CT)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>Fludeoxyglucose (18F)</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Carbohydrate High Fat Diet</intervention_name>
    <description>low carbohydrate and high fat diet for 48-72 hours</description>
    <arm_group_label>Observational (diet, FDG PET CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo FDG PET CT</description>
    <arm_group_label>Observational (diet, FDG PET CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Endomyocardial biopsy specimen&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients being treated with ICI and presenting to the University of Texas MD Anderson&#xD;
        Cancer Center (MDACC) with suspected ICI-related myocarditis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of age &gt;= 18 years&#xD;
&#xD;
          -  Patients must be able to understand and be willing to sign a written informed consent&#xD;
             document. Surrogate decision-makers of patients will be allowed to consent patients&#xD;
             for this study&#xD;
&#xD;
          -  Patients must be receiving or have a history of receiving any ICI therapy in&#xD;
             monotherapy or combination therapy&#xD;
&#xD;
          -  Patients must have a suspicion of ICI-related myocarditis either by clinical&#xD;
             presentation, biomarkers, or other diagnostic modalities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating patients will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas L Palaskas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas L Palaskas, MD</last_name>
    <phone>713-563-3532</phone>
    <email>nlpalaskas@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas L. Palaskas</last_name>
      <phone>713-563-3532</phone>
      <email>nlpalaskas@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Nicolas L. Palaskas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

